Clinical Trials Logo
  1. Home
  2. Malignant Solid Tumour
  3. NCT02853903

Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors

Malignant Solid Tumour Clinical Trial

Clinical Trial Summary

The aim of this study is the efficacy of autogenic and allogenic natural killer (NK) immunotherapy on recurrent solid tumors.

Clinical Trial Description

By enrolling patients with multiple kinds of solid tumor adapted to enrolled criteria, this study will document for the first time the short/long term efficacy of auto/allogenic NK cells.The outcome will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02853903
Study type Interventional
Source Fuda Cancer Hospital, Guangzhou
Contact
Status Completed
Phase Phase 2
Start date July 1, 2016
Completion date July 1, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT01721148 - A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours Phase 1
Completed NCT00551096 - Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors Phase 1
Completed NCT01023737 - Hydroxychloroquine + Vorinostat in Advanced Solid Tumors Phase 1
Completed NCT01435096 - BN80927 in Patients With Advanced Malignant Solid Tumors Phase 1
Completed NCT01951846 - To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours Phase 1
Completed NCT01325558 - A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT01554371 - Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies Phase 1/Phase 2
Recruiting NCT01286896 - Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT01309490 - Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients Phase 1/Phase 2
Completed NCT00635791 - Phase I Study of Vorinostat and Sorafenib in Advanced Cancer Phase 1
Completed NCT01376505 - Vaccine Therapy in Treating Patients With Metastatic Solid Tumors Phase 1
Completed NCT00388427 - Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies Phase 1
Completed NCT01611857 - Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach Phase 1/Phase 2
Completed NCT02843204 - Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors Phase 1/Phase 2
Completed NCT01618136 - An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT00801151 - Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer Phase 1
Completed NCT02786628 - Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation
Completed NCT01184807 - Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors Phase 1
Completed NCT00969410 - A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases Phase 1
Completed NCT02857920 - Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors Phase 1/Phase 2